MB-CART19.1

DRUG10 trials

Sponsors

Miltenyi Biomedicine GmbH, Centre Hospitalier Universitaire De Lille, Centre Hospitalier Universitaire De Montpellier, Shanghai Children's Medical Center, King Hussein Cancer Center

Conditions

Acute Lymphatic LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia Not Having Achieved RemissionAcute Lymphoblastic Leukemia RecurrentAcute Lymphoblastic Leukemia RefractoryAcute Lymphoblastic Leukemia With Failed RemissionB-cell Lymphoma RecurrentB-cell Lymphoma Refractory

Phase 1

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Active, not recruitingNCT03853616

Miltenyi Biomedicine GmbHAcute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory +2

Start: 2018-11-26End: 2026-03-31Target: 48Updated: 2025-11-24

Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies

RecruitingCTIS2022-501648-14-00

Miltenyi Biomedicine GmbHadult NHL/chronic lymphatic leukemia [CLL]), aggressive NHL), Relapsed or refractory B cell non-Hodgkins lymphoma (NHL) +4

Start: 2024-05-05Target: 40Updated: 2025-07-18

MB-CART19.1 in Refractory SLE

RecruitingNCT06189157

Miltenyi Biomedicine GmbHSLE - Systemic Lupus Erythematosus

Start: 2024-08-12End: 2027-09-30Target: 29Updated: 2025-11-26

CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE

RecruitingCTIS2024-516819-24-00

Miltenyi Biomedicine GmbHIdiopathic Inflammatory Myopathy, Systemic Lupus Erythematosus, Systemic Sclerosis

Start: 2023-05-16Target: 33Updated: 2025-07-08

A phase I safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies

Active, not recruitingCTIS2024-513334-38-00

Miltenyi Biomedicine GmbHadult NHL/chronic lymphatic leukemia [CLL]), aggressive NHL), Refractory/relapsed B-NHL +2

Start: 2018-05-15Target: 49Updated: 2025-07-17

CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed AML expressing CD19.”

RecruitingCTIS2023-509212-29-01

Centre Hospitalier Universitaire De LillePatients (male or female) ≥18 years old with R/R AML that expresses CD19 by Flow-cytometry

Start: 2025-07-10Target: 5Updated: 2025-10-20

Phase 2

MB-CART19.1 in Patients With R/R ALL

Shanghai Children's Medical CenterPrecursor B-Lymphoblastic Lymphoma/Leukaemia Refractory

Start: 2017-12-01End: 2019-12-31Target: 10Updated: 2017-10-25

A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR

Not yet recruitingCTIS2024-519511-33-00

Centre Hospitalier Universitaire De Montpellierazathioprine, mycophenolate mofetil) and/or a biological DMARD (rituximab or tocilizumab) for at least 6 months., Patients will be included with a stable but active disease (as defined Diagnosis of systemic sclerosis according to ACR/EULAR classification by EUSTAR ≥2.5) or to patients with a worsening disease despite low dose steroids and at least 2 immunosuppressive treatment including DMARDs (methotrexate

Target: 6Updated: 2025-11-07

Unknown Phase

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

RecruitingNCT06508775

Miltenyi Biomedicine GmbHAcute Lymphatic Leukemia, B-cell Non Hodgkin Lymphoma, Childhood Non-Hodgkin Lymphoma +4

Start: 2024-05-05End: 2040-12-31Target: 40Updated: 2025-11-26

MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

RecruitingNCT07371403

King Hussein Cancer CenterAcute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia Recurrent +2

Start: 2026-02-01End: 2029-01-01Target: 12Updated: 2026-03-25